Hepatic venous pressure gradient in hepatic resection for hepatocellular carcinoma

Abstract

Liver transplantation is considered the gold standard for curative treatment of hepatocellular carcinoma (HCC) in patients with cirrhosis, but limited organ availability and high costs necessitate alternative options. Hepatic resection (HR) is preferred for select patients, providing tumor removal and prognostic information. However, HR has been associated with life-threatening complications, especially in the presence of clinically significant portal hypertension (CSPH). Current guidelines recommend HR only for patients with well-preserved liver function, normal bilirubin levels, good performance status, and no CSPH. However, advancements in surgical techniques and portal hypertension management are challenging these guidelines, potentially allowing the consideration of hepatic resection for HCC in cirrhotic patients with CSPH. Indeed, minimally invasive approaches improve safety and outcomes for selected CSPH patients and accurate assessment of CSPH allows risk stratification according to liver function, tumor location, and extent of resection. Thus, despite the negative impact of CSPH on HR outcomes, careful patient selection and minimally invasive techniques expand the potential for HR in CSPH patients. This comprehensive review examines the evidence on HR in HCC treatment for cirrhotic patients with CSPH, highlighting challenges in surgical decision-making, the importance of direct measurement of hepatic venous pressure gradient, and exploring the benefits and risks associated with HR. Moreover, it underscores the need for refined prediction models and algorithms to optimize patient selection and enhance surgical outcomes.

Keywords

Hepatocellular carcinoma / hepatic resection / hepatic venous pressure gradient / clinically significant portal hypertension / unresolved postoperative hepatic decompensation

References

[1] Forner A,Bruix J.Hepatocellular carcinoma.Lancet2018;391:1301-14

[2] D'Amico G,Pagliaro L.Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.J Hepatol2006;44:217-31

[3] European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the LiverEASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[4] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[5] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[6] Berzigotti A,Abraldes JG,Bruix J.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.Hepatology2015;61:526-36

[7] Bosch J,Berzigotti A.The clinical use of HVPG measurements in chronic liver disease.Nat Rev Gastroenterol Hepatol2009;6:573-82

[8] Llovet JM,Bruix J.Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation.Hepatology1999;30:1434-40

[9] Ishizawa T,Aoki T.Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.Gastroenterology2008;134:1908-16

[10] Bruix J,Bosch J.Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure.Gastroenterology1996;111:1018-22

[11] Citterio D,Sposito C,Bhoori S.Hierarchic interaction of factors associated with liver decompensation after resection for hepatocellular carcinoma.JAMA Surg2016;151:846-53

[12] de Franchis R,Garcia-Tsao G,Ripoll C.Baveno VII FacultyBaveno VII - Renewing consensus in portal hypertension.J Hepatol2022;76:959-74

[13] Tsochatzis EA,Burroughs AK.Liver cirrhosis.Lancet2014;383:1749-61

[14] Hernández-Gea V,Colomo A.Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers.Am J Gastroenterol2012;107:418-27

[15] Villanueva C,Genescà J.β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial.Lancet2019;393:1597-608

[16] Villanueva C,Colomo A.Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding.Gastroenterology2009;137:119-28

[17] Villanueva C,Aracil C.A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.Hepatology2017;65:1693-707

[18] Reverter E,Albillos A.The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery.J Hepatol2019;71:942-50

[19] de Franchis R.Baveno VI FacultyExpanding consensus in portal hypertension: report of the Baveno VI consensus workshop: Stratifying risk and individualizing care for portal hypertension.J Hepatol2015;63:743-52

[20] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[21] Boleslawski E,Truant S.Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis.Br J Surg2012;99:855-63

[22] Hernandez-Gea V,Berzigotti A.Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension.World J Gastroenterol2013;19:1193-9 PMCID:PMC3587475

[23] Llop E,Reig M.Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.J Hepatol2012;56:103-8

[24] Ganne-Carrié N,Chapel F.Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis.Hepatology1996;23:1112-8

[25] Nakayama H,Miyake H,Yokoyama E.Endoscopic prediction of hepatocellular carcinoma by evaluation of bleeding esophageal varices.Digestion2004;70:233-9

[26] Ripoll C,Garcia-Tsao G.Portal Hypertension Collaborative GroupHepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis.J Hepatol2009;50:923-8 PMCID:PMC3721146

[27] Abraldes JG,Loureiro-Silva M,Sessa WC.Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state.Am J Physiol Gastrointest Liver Physiol2006;290:G980-7

[28] The Cancer of the Liver Italian Program (Clip) InvestigatorsA new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators.Hepatology1998;28:751-5

[29] Zanetto A,Spiezia L,Simioni P.Cancer-Associated thrombosis in cirrhotic patients with hepatocellular carcinoma.Cancers2018;10:450 PMCID:PMC6266984

[30] Figueras J,Ruiz D.Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial.Ann Surg2005;241:582-90 PMCID:PMC1357061

[31] Choi SB,Song TJ,Choi SY.Influence of clinically significant portal hypertension on surgical outcomes and survival following hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis.J Hepatobiliary Pancreat Sci2014;21:639-47

[32] Tang YH,Wen TF.Influence of clinically significant portal hypertension on hepatectomy for hepatocellular carcinoma: a meta-analysis.Asian Pac J Cancer Prev2014;15:1649-54

[33] Cucchetti A,Pinna AD.Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. more doubts than clarity.Hepatology2015;62:976-7

[34] Ferrer-Fàbrega J,Liccioni A.Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.Hepatology2016;63:839-49

[35] Llovet JM,Pikarsky E.Hepatocellular carcinoma.Nat Rev Dis Primers2016;2:16018

[36] Morise Z,Cherqui D,Belli G.Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease.J Hepatobiliary Pancreat Sci2015;22:342-52

[37] Vitale A.Towards a personalized approach to hepatic resection in cirrhotic patients.J Hepatol2019;71:859-61

[38] Vitali GC,Terraz S.Minimally invasive surgery versus percutaneous radio frequency ablation for the treatment of single small (≤ 3 cm) hepatocellular carcinoma: a case-control study.Surg Endosc2016;30:2301-7

[39] Wu X,Lau WY.Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study.Surg Endosc2019;33:206-15

[40] Lee DH,Park YH,Kim JS.Long-term surgical outcomes in patients with hepatocellular carcinoma undergoing laparoscopic vs. open liver resection: a retrospective and propensity score-matched study.Asian J Surg2021;44:206-12

[41] Haruki K,Fujiwara Y.Effectiveness of anatomical resection for small hepatocellular carcinoma: a propensity score-matched analysis of a multi-institutional database.J Gastrointest Surg2021;25:2835-41

[42] Vitale A,Frigo AC.Italian Liver Cancer (ITALI.CA) groupSurvival benefit of liver resection for patients with hepatocellular carcinoma across different barcelona clinic liver cancer stages: a multicentre study.J Hepatol2015;62:617-24

[43] Xiao H,Mei B.Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation.Medicine2015;94:e495 PMCID:PMC4554177

[44] Zhong JH,Gong WF.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.Ann Surg2014;260:329-40

[45] Cucchetti A,Trevisani F.Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients.World J Gastroenterol2012;18:6398-408 PMCID:PMC3508634

[46] Cucchetti A,Golfieri R.Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma.J Hepatol2016;64:79-86

[47] Fuks D,Paradis V,Durand F.Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis.Hepatology2012;55:132-40

[48] Imamura H,Tanaka E.Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.J Hepatol2003;38:200-7

[49] Sala M,Llovet JM.Barcelona Clinic Liver Cancer (BCLC) GroupHigh pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.Liver Transpl2004;10:1294-300

[50] Truant S,Hebbar M.Laparoscopic resection vs. open liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: a case-matched study.Surg Endosc2011;25:3668-77

[51] Casellas-Robert M,Lopez-Ben S.Laparoscopic liver resection for hepatocellular carcinoma in child-pugh a patients with and without portal hypertension: a multicentre study.World J Surg2020;44:3915-22

[52] Cherqui D,Tayar C.Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives.Ann Surg2006;243:499-506 PMCID:PMC1448957

[53] Lim C,Lahat E.Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study.Surg Endosc2019;33:811-20

[54] Soubrane O,Laurent A.Laparoscopic resection of hepatocellular carcinoma: a French survey in 351 patients.HPB2014;16:357-65 PMCID:PMC3967888

[55] Xiong JJ,Javed MA.Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma.World J Gastroenterol2012;18:6657-68 PMCID:PMC3516221

[56] Morise Z.Perspective of laparoscopic liver resection for hepatocellular carcinoma.World J Gastrointest Surg2015;7:102-6 PMCID:PMC4513431

[57] Sotiropoulos GC,Kostakis ID.Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma.Updates Surg2017;69:291-311

[58] Sotiropoulos GC,Machairas N.Meta-analysis of laparoscopic vs open liver resection for hepatocellular carcinoma: the European experience.J BUON2017;22:1160-71

[59] Azoulay D,Casellas-Robert M.Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension.JHEP Rep2021;3:100190 PMCID:PMC7689549

[60] Lim C,Osseis M.Short-term outcomes following hepatectomy for hepatocellular carcinoma within and beyond the BCLC guidelines: a prospective study.HPB2018;20:222-30

[61] Molina V,Ferrer J.Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.Surg Endosc2018;32:2345-54

[62] Roayaie S,Tabrizian P.The role of hepatic resection in the treatment of hepatocellular cancer.Hepatology2015;62:440-51

[63] Zhong JH,Xiao N.Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension.PLoS One2014;9:e108755 PMCID:PMC4182657

[64] Yang T,Zhang H,Shen F.Should surgery be carried out in patients with hepatocellular carcinoma with portal hypertension?.Hepatology2015;62:976

[65] Zhong JH.Portal hypertension should not be a contraindication of hepatic resection to treat hepatocellular carcinoma with compensated cirrhosis.Hepatology2015;62:977-8

[66] He W,Zheng Y.The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis.BMC Cancer2015;15:263 PMCID:PMC4399206

[67] Kim SU,Park JY.Prediction of postoperative hepatic insufficiency by liver stiffness measurement (FibroScan((R))) before curative resection of hepatocellular carcinoma: a pilot study.Hepatol Int2008;2:471-7 PMCID:PMC2716908

[68] Zhong JH,Wang YY.Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours, or portal hypertension.Gut2015;64:520-1

[69] Leitch AG,Ringel EW.Immunologically induced generation of tetraene and pentaene leukotrienes in the peritoneal cavities of menhaden-fed rats.J Immunol1984;132:2559-65

[70] Prodeau M,Duhamel A.An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy.J Hepatol2019;71:920-9

[71] Meng XQ,Xia Y.A nomogram for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma based on spleen-volume-to-platelet ratio.Asian J Surg2023;46:399-404

[72] Berardi G,Sposito C.Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in child-pugh B cirrhosis.J Hepatol2020;72:75-84

[73] Han HS,Ahn S,Cho JY.Laparoscopic versus open liver resection for hepatocellular carcinoma: case-matched study with propensity score matching.J Hepatol2015;63:643-50

[74] Sposito C,Facciorusso A.Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma.Br J Surg2016;103:871-80

[75] Zhou J,Wang Z.Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition).Liver Cancer2020;9:682-720 PMCID:PMC7768108

[76] Johnson PJ,Kagebayashi C.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.J Clin Oncol2015;33:550-8 PMCID:PMC4322258

[77] Pinato DJ,Allara E.The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.J Hepatol2017;66:338-46

[78] Castera L,Alberti A.Non-invasive evaluation of liver fibrosis using transient elastography.J Hepatol2008;48:835-47

[79] Robic MA,Métivier S.Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study.J Hepatol2011;55:1017-24

[80] Cescon M,Cucchetti A.Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma.Ann Surg2012;256:706-12; discussion 712

[81] Procopet B,Horhat A.Good performance of liver stiffness measurement in the prediction of postoperative hepatic decompensation in patients with cirrhosis complicated with hepatocellular carcinoma.Med Ultrason2018;20:272-7

[82] Berzigotti A,Arena U.Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.Gastroenterology2013;144:102-11.e1

[83] Arai Y,Albrecht P.Modulation of cardiac autonomic activity during and immediately after exercise.Am J Physiol1989;256:H132-41

[84] Buechter M,Theysohn JM,Canbay A.Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation.Dig Liver Dis2018;50:54-60

[85] Abraldes JG,Stefanescu H.Anticipate InvestigatorsNoninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the "anticipate" study.Hepatology2016;64:2173-84

[86] Pons M,Scheiner B.Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease.Am J Gastroenterol2021;116:723-32